Skip to NavigationSkip to content

Takeda launches Actos combination in UK

Published on 26/10/06 at 01:51pm

 

Takeda has expanded its type II diabetes portfolio in the UK with the launch of Competact, a combination of the company's Actos and an older treatment metformin.

Actos (pioglitazone) is one of two glitazones on the market and Takeda faces stiff competition from the other - GlaxoSmithKline's Avandia (rosiglitazone).

The class has proved a notoriously difficult one in which to develop new products  Takeda, GSK, Novo Nordisk, Merck, Bristol-Myers Squibb Merck and AstraZeneca have all seen products fail either in late-stage clinical trials or at the hands of regulators.

Takeda's Competact is indicated to treat patients with type II diabetes who are unable to achieve sufficient glycaemic control with their highest tolerated dose of metformin.

Professor Tony Barnett, Professor of Medicine at the University of Birmingham, said: "The combination of metformin and pioglitazone is a logical clinical choice.  Clinical trial data suggest that metformin and pioglitazone improve cardiovascular risk factors in patients with type II diabetes.

"This means that Competact may be particularly useful in patients at high cardiovascular risk, including those who have already had a cardiovascular event."

In launching its Actos/metformin combination, Takeda is a few years behind GSK, whose own metformin combination Avandamet arrived in the UK in 2003. GSK also markets Avandaryl, which combines Avandia with the  sulfonylurea, glimepiride, and was approved in the US earlier this year.

With Competact, Takeda will be looking to narrow the UK sales gap between Actos and Avandia, both of which were approved in 2000.

Last year, the NHS spent £14.8 million on prescriptions for Actos in the community in England compared to £44.7 million  on Avandia.

Takeda was the fastest growing UK pharma company of its size in 2005. Figures from IMS Health show its sales grew by 25% in the six months to June 2006 compared to the same period in 2005.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches